Terapijski pristup liječenju kronične opstrukcijske plućne bolesti u vrijeme pandemije COVID-19

Professional paper - Professional paper

• Author: Iva Križanović
• Author: Anita Somborac Bačura
• Author's institution: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Centre for applied pharmacy)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract (english)

Chronic obstructive pulmonary disease (COPD) is a common
lung disease that is characterized by long-term respiratory
symptoms and airflow limitation. It is important to investigate whether patients
with COPD are at the increased risk of infection with SARS-Co V -2 and what are
the clinical outcomes of coronavirus disease 2019 (COVID-19). Since both diseases
affect the respiratory tract, the purpose of this review was to determine
whether there is an interrelationship between COPD and COVID-19. Currently,
it is not clear whether COPD patients are at higher risk of SARS-Co V-2 infection;
however, it is confirmed that, if they are affected by COVID-19, there is a
higher rate of hospitalisation and death. COPD patients should continue prescribed
COPD therapy even if they have COVID-19 infection because it is not
confirmed that taking these medications changes the clinical outcomes of
COVID-19 infection. Protective measures are very important in times of higher
prevalence of COVID-19 since they reduce the risk of infection and help COPD
patients maintain their health.

• Keywords (croatian): COVID-19; KOPB; kronična opstrukcijska plućna bolest
• Language: croatian
• Publication type: Professional paper - Professional paper
• Publication status: Published
• Peer review: Peer review - domestic
• Publication version: Published version
• Journal title: Farmaceutski glasnik
• Numbering: vol. 78, no. 7-8, pp. 349-360
• p-ISSN: 0014-8202
• URN:NBN: urn:nbn:hr:163:124621
• Publication: 2022
• Type of resource: Text
• Access conditions: Open access
• Created on: 2022-09-08 15:43:35